RESIST-TB released its July 2021 newsletter with the latest research publications on drug-resistant TB.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Australian researchers at the Kirby Institute at UNSW Sydney, Doherty Institute and Burnet Institute, along with international organisations, the Clinton Health Access Initiative and Foundation for Innovative New Diagnostics, have been awarded $5.2 million to strengthen laboratory capacity for testing and diagnosis of COVID-19, HIV, malaria and tuberculosis in the Indo-Pacific region.

The Ministry of Health of Indonesia released TB Care School Guidelines to support the efforts to prevent the TB transmission in schools. For more information, click here.

Researchers from the University of Maryland found a gene that helps tuberculosis turn off an important immune signaling system in infected human cells.

Episode 4 of the podcast series, The Dose, by the Stop TB Partnership's Working Group on New TB Drugs (WGND) is now available online. Shobha Shukla speaks with TB regimen development experts Dr. Debra Hanna and Dr. Robert Bates on the topic of the PAN-TB collaboration and novel regimen development.

The National Institutes of Health (NIH) has renewed grants to seven regional centers that compose the International epidemiology Databases to Evaluate AIDS (IeDEA), awarding $20.8 million in first-year funding. The 15-year-old IeDEA program efficiently advances knowledge about HIV by pooling and analyzing de-identified health data from more than two million people with HIV on five continents to answer research questions that individual studies cannot address. The grants are expected to last five years and to total an estimated $100 million.  

Developing drugs to combat tuberculosis, or TB, can be frustrating business. A gene essential to the bacteria’s lifecycle is discovered, scientists rush to develop drugs that inhibit the target, and then—disappointment. Volleys of compounds hurled at the essential gene target have little impact on microbial growth. The bacteria live on. The scientists return to the drawing board. 

BioNTech SE said it would invest some of the profits from the Covid-19 vaccine it markets with Pfizer Inc. into developing shots for malaria and tuberculosis in Africa, part of the German company’s plan to establish a large production hub for innovative medicines on the continent.

CHMP grants positive opinion in the European Union for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba® (delamanid) for the paediatric population weighing at least 10 kg with pulmonary multidrug-resistant TB